Reuters logo
BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests
November 28, 2017 / 1:09 PM / 19 days ago

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

Nov 28 (Reuters) - Genomic Health Inc:

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

* GENOMIC HEALTH-DEAL TO PROVIDE CO WITH EXCLUSIVE GLOBAL RIGHTS TO DEVELOP CANCER TESTS BASED ON CLEVELAND DIAGNOSTICS’ ISOPSA REAGENT & SIA TECHNOLOGY​

* GENOMIC HEALTH INC - ‍GENOMIC HEALTH IS EXPECTED TO BEGIN ADDITIONAL DEVELOPMENT AND CLINICAL VALIDATION OF FIRST HIGH-PSA REFLEX TEST IN 2018​

* GENOMIC HEALTH INC - ‍GENOMIC HEALTH WILL MAKE A CONVERTIBLE NOTE INVESTMENT IN CLEVELAND DIAGNOSTICS IN PRINCIPAL AMOUNT OF $2 MILLION IN Q4 OF 2017​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below